Month: February 2021

The Chefs’ Warehouse Reports Fourth Quarter 2020 Financial Results

Written by Customer Service on February 10, 2021. Posted in Public Companies.

RIDGEFIELD, Conn., Feb. 10, 2021 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs’”), a premier distributor of specialty food products in the United States and Canada, today reported financial results for its fourth quarter ended December 25, 2020.Financial highlights for the fourth quarter of 2020:Net sales decreased 34.0% to $281.7 million for the fourth quarter of 2020 from $426.5 million for the fourth quarter of 2019. On a sequential quarter basis, net sales grew 10.9% or $27.6 million compared to the third quarter of fiscal 2020.GAAP net loss was $37.1 million, or $(1.02) per diluted share, for the fourth quarter of 2020 compared to net income of $10.9 million, or $0.36 per diluted share, in the fourth quarter of 2019.Adjusted EPS1 was $(0.52) for the fourth quarter of 2020 compared to...

Kamada Reports Fourth Quarter and Fiscal Year 2020 Financial Results, Recent Achievements and Corporate Development Activities

Written by Customer Service on February 10, 2021. Posted in Public Companies.

Full-Year 2020 Revenues were $133.2 Million, In-Line with the Company’s Guidance; Adjusted EBITDA for 2020 was $25.1 MillionKamada Enters U.S. Plasma Collection Market Through Acquisition of an FDA-Approved Facility, Furthering its Strategic Goal of Becoming a Fully Integrated Specialty Plasma Company Focused on Growing its Hyperimmune IgG PortfolioIsraeli Ministry of Health (IMOH) Initiated Treatment of Hospitalized COVID-19 Patients with Kamada’s Plasma-Derived COVID-19 Immunoglobulin (IgG) Investigational Product Primarily as Part of a Multi-Center Clinical Study Led by the IMOH; Current Planned Supply to IMOH is Sufficient to Treat an Estimated 500 PatientsKamada Continues to Expand Existing Business Lines as Evidenced by the Recent Additions to its Israeli Distribution Biosimilar Products Portfolio; Also Exploring Business Development...

Awilco Drilling PLC: Q4 2020 Presentation

Written by Customer Service on February 10, 2021. Posted in Earnings Releases And Operating Results.

Please find attached the Q4 2020 presentation to be held in the digital meeting today, 10 February, at 13:00 UK time (14:00pm CET / 08:00 EST).To join the digital meeting, please click this link or copy and paste the following address into your browser:https://teams.microsoft.com/l/meetup-join/19%3ameeting_ZDU1M2ZkMzYtNjQwNi00NTU1LTg5OTctM2IzMjUxMmY3Y2Iy%40thread.v2/0?context=%7b%22Tid%22%3a%22c6903860-15d6-4675-a5fe-cf03764de020%22%2c%22Oid%22%3a%22b70a3a9b-a081-41f9-b2a4-3e57ef82979e%22%2c%22IsBroadcastMeeting%22%3atrue%7dAberdeen, 10 February 2021For further information please contact:Eric Jacobs, interim CEOPhone: +44 1224 737900Cathrine Haavind, IR ManagerPhone: +47 93 42 84 64Email: ch@awilcodrilling.comThis information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.AttachmentAWDR...

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

Written by Customer Service on February 10, 2021. Posted in Public Companies.

VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has decided to review its protocol for its phase 2b/3 study of Ifenprodil for COVID-19, to consider adding lung scarring as an additional endpoint if sufficient data is available from a significant number of patients.When Algernon wrote its original phase 2b/3 protocol last April 2020, lung scarring, post hospital release, had not yet been established as a major problem with recovering COVID-19 patients, so it was not included.Each hospital that participated in the COVID-19 study was left to manage their site-specific standard of care protocol for releasing a patient. While most hospitals...

Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares

Written by Customer Service on February 10, 2021. Posted in Public Companies.

LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the pricing of an underwritten public offering of 34,500,000 American Depositary Shares (“ADSs”) at a public offering price of $2.90 per ADS. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $100.1 million. In addition, Mereo has granted the underwriters a 30-day option to purchase up to 5,175,000 additional ADSs at the public offering price, less underwriting discounts and commissions. Each ADS represents five ordinary shares of Mereo. All of the ADSs in the offering will be sold by Mereo. The offering is expected...

Mesa Partners with United and Archer to Combat Climate Change

Written by Customer Service on February 10, 2021. Posted in Public Companies.

PHOENIX, Feb. 10, 2021 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA), in partnership with United Airlines, announced it will be working with Archer, the world’s leading urban air mobility company, to advance the adoption of sustainable flight in regional aviation.Since its founding, Mesa has been a leader in introducing new technology to regional aviation. Mesa’s expertise in operating regional service and navigating the regulatory process necessary to help certify new aircraft makes it well-positioned to lead an important challenge facing the industry– decarbonizing regional air travel. Integrating sustainable aircraft into its fleet continues the evolution of technology that has typified the regional aviation landscape as illustrated by the transition from five-passenger piston aircraft to turboprop and jet aircraft,...

Interpublic Increases Common Stock Dividend for Ninth Consecutive Year

Written by Customer Service on February 10, 2021. Posted in Dividend Reports And Estimates.

New York, Feb. 10, 2021 (GLOBE NEWSWIRE) — Interpublic Group (NYSE: IPG) today announced that the company’s Board of Directors has declared a quarterly dividend on IPG common stock of $0.27 per share, payable on March 15, 2021, to holders of record at the close of business on March 1, 2021. The increase in the dividend from $0.255 to $0.27 per share represents a 6 percent increase to the Company’s quarterly dividend.# # #About InterpublicInterpublic is values-based, data-fueled, and creatively-driven. Major global brands include Acxiom, Craft, FCB (Foote, Cone & Belding), FutureBrand, Golin, Huge, Initiative, Jack Morton, Kinesso, MAGNA, Matterkind, McCann, Mediahub, Momentum, MRM, MullenLowe Group, Octagon, R/GA, UM and Weber Shandwick. Other leading brands include Avrett Free Ginsberg, Campbell Ewald, Carmichael Lynch, Deutsch,...

L’OREAL: Disclosure of total number of voting rights and number of shares in the capital at 31 january 2021

Written by Customer Service on February 10, 2021. Posted in Public Companies.

Société anonyme au capital de 111 974 316 eurosSiège social : 14, rue Royale, 75008 Paris632 012 100 R.C.S. ParisLegal Entity Identifyer : 529900JI1GG6F7RKVI53 Disclosure of total number of voting rights and number of sharesin the capital at 31 January 2021 Pursuant to article L-233-8 II of the French “Code de Commerce” and 223-16 of the AMF’s General Regulations: (*) pursuant to article 223-11 of the AMF’s General Regulations About L’OréalL’Oréal has devoted itself to beauty for over 110 years. With its unique international portfolio of 36 diverse and complementary brands, the Group generated sales amounting to 29.9 billion euros in 2019 and employs 88,000 people worldwide. As the world’s leading beauty company, L’Oréal is present across all distribution networks: mass market, department stores, pharmacies and drugstores,...

L’OREAL : Déclaration du nombre total de droits de vote et du nombre d’actions composant le capital au 31 janvier 2021

Written by Customer Service on February 10, 2021. Posted in Public Companies.

Société anonyme au capital de 111 974 316 eurosSiège social : 14, rue Royale, 75008 Paris632 012 100 R.C.S. ParisLegal Entity Identifyer : 529900JI1GG6F7RKVI53 Déclaration du nombre total de droits de vote et du nombre d’actions composant le capital au 31 janvier 2021 Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers.(*) en application de l’article 223-11 du Règlement Général de l’Autorité des Marchés Financiers À propos de L’OréalDepuis plus de 110 ans, L’Oréal est dédié au métier de la beauté. Avec un portefeuille international de 36 marques diverses et complémentaires, le Groupe a réalisé en 2019 un chiffre d’affaires consolidé de 29,9 milliards d’euros et compte 88 000 collaborateurs dans le monde. Leader mondial de la beauté, L’Oréal...

Maravai LifeSciences Expands Its Intellectual Property Portfolio

Written by Customer Service on February 10, 2021. Posted in Public Companies.

SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that the United States Patent and Trademark Office has issued a new patent, United States Patent No. 10,913,768, to the company’s TriLink Biotechnologies subsidiary.The patent covers advancements in TriLink’s CleanCap® technology for the co-transcriptional capping of messenger RNAs (mRNAs). This patent is the third U.S. patent that has issued to the company related to the CleanCap technology. Capping is an important step in the production of synthetic mRNA, which is used to develop nucleic acid vaccines and therapeutics that deliver instructions to human cells to produce proteins that may prevent or correct disease.The technology described...

Month: February 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals